This Article Full Text Full Text (PDF) All Versions of this Article: 114/23/2498    most recent CIRCULATIONAHA.106.630129v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vercauteren, M. Articles by Richard, V. Search for Related Content PubMed PubMed Citation Articles by Vercauteren, M. Articles by Richard, V. Related Collections Congestive Cell signalling/signal transduction Heart failure - basic studies Endothelium/vascular type/nitric oxide

(Circulation. 2006;114:2498-2507.)
© 2006 American Heart Association, Inc.

Vascular Medicine

Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure

Magali Vercauteren, BSc; Elise Remy, PharmD; Corinne Devaux, PhD; Brigitte Dautreaux, BSc; Jean-Paul Henry, BSc; Fabrice Bauer, MD; Paul Mulder, PhD; Rob Hooft van Huijsduijnen, PhD; Agnès Bombrun, PhD; Christian Thuillez, MD, PhD; Vincent Richard, PhD

From INSERM U644, Federate Institute for Multidisciplinary Research on Peptides, Rouen University Medical School, Rouen, France (M.V., E.R., C.D., B.D., J.H., F.B., P.M., C.T., V.R.); and Serono Pharmaceutical Research Institute, Geneva, Switzerland (R.H.v.H., A.B.).

Correspondence to Vincent Richard, PhD, INSERM U644, UFR Médecine-Pharmacie de Rouen, 22 Boulevard Gambetta, 76183 Rouen, France. E-mail Vincent.Richard{at}univ-rouen.fr

Received March 29, 2006; revision received September 22, 2006; accepted September 29, 2006.

Background— Chronic heart failure (CHF) induces endothelial dysfunction characterized by a decrease in nitric oxide (NO) production in response to flow (flow-mediated dilatation [FMD]). Because activation of endothelial NO synthase (eNOS) by flow requires tyrosine phosphorylation, we tested whether endothelial dysfunction could be corrected by increasing phosphotyrosine levels using protein tyrosine phosphatase (PTP) inhibitors and especially inhibitors of PTP1B.

Methods and Results— CHF was induced by coronary ligation in mice, and FMD was assessed in isolated and cannulated mesenteric artery segments (2 mm in length and <300 µm in diameter). CHF almost abolished FMD but only moderately affected the response to acetylcholine. In mice with CHF, the PTP1B inhibitors AS279, AS098, and AS713 restored FMD to levels similar to those of normal mice. This restoration was reduced by inhibitors of eNOS and phosphatidylinositol-3 kinase. Polymerase chain reaction and Western blot showed that arteries express PTP1B, and this expression was not affected by CHF. Immunolocalization revealed the presence of PTP1B in the endothelium and the adventitia. Flow induced a transient eNOS phosphorylation that was absent in CHF. PTP1B inhibition stimulated early eNOS phosphorylation and increased phosphorylation of Akt.

Conclusions— Our results demonstrate for the first time that PTP1B inhibitors may be potent treatments for endothelial dysfunction.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				E. J. Belin de Chantemele, K. Muta, J. Mintz, M. L. Tremblay, M. B. Marrero, D. J. Fulton, and D. W. Stepp Protein Tyrosine Phosphatase 1B, a Major Regulator of Leptin-Mediated Control of Cardiovascular Function Circulation, September 1, 2009; 120(9): 753 - 763. [Abstract] [Full Text] [PDF]

				P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]

				Y. Nakamura, N. Patrushev, H. Inomata, D. Mehta, N. Urao, H. W. Kim, M. Razvi, V. Kini, K. Mahadev, B. J. Goldstein, et al. Role of Protein Tyrosine Phosphatase 1B in Vascular Endothelial Growth Factor Signaling and Cell-Cell Adhesions in Endothelial Cells Circ. Res., May 23, 2008; 102(10): 1182 - 1191. [Abstract] [Full Text] [PDF]

				V. Leblais, E. Delannoy, F. Fresquet, H. Begueret, N. Bellance, S. Banquet, C. Allieres, L. Leroux, C. Desgranges, A. Gadeau, et al. {beta}-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent {beta}2 component in pulmonary hypertension Cardiovasc Res, January 1, 2008; 77(1): 202 - 210. [Abstract] [Full Text] [PDF]

				F. Krotz, H.-Y. Sohn, and H. Mannell Letter by Krotz et al Regarding Article, "Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure" Circulation, June 26, 2007; 115(25): e648 - e648. [Full Text] [PDF]

				M. Vercauteren, E. Remy, C. Devaux, B. Dautreaux, J.-P. Henry, F. Bauer, P. Mulder, C. Thuillez, V. Richard, R. Hooft van Huijsduijnen, et al. Response to Letter Regarding Article, "Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure" Circulation, June 26, 2007; 115(25): e649 - e649. [Full Text] [PDF]

				C. J Bailey Treating insulin resistance: future prospects Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 20 - 31. [Abstract] [PDF]